Mitotech Ltd, a mitochondria-focused clinical-stage biotechnology company, announced its presentationat LSX World Congress 2024. The biotechnology conference will take place on April 29-30, 2024 in London, UK.
“We look forward to presenting our new data from Obesity models this year at the LSX Congress. This event is the perfect opportunity to demonstrate recent weight loss data for our lead compound SkQ1 both as a standalone treatment and in combination with GLP-1 agonists,” said Natalia Perekhvatova, the CEO of Mitotech Ltd.
About Mitotech Ltd
Mitotech Ltd is a UK-based late clinical stage biotechnology company developing mitochondria-targeted drugs to treat metabolic and neurodegenerative disorders. Mitotech’s products are based on novel small molecules that inhibit ferroptosis within mitochondria.